When the Statin Strikes Twice: Atorvastatin-Induced Autoimmune Hepatitis Confirmed by Inadvertent Rechallenge (ACG 2026) - Aug 29, 2026 - Abstract #P6374; Pres time: Oct 13, 2026; 10:30 AM - 04:00 PM; Location: Exhibit Halls A - D (Level 3); "Atorvastatin was discontinued, she received steroid with improvement, and she was transitioned to evolocumab. The lesson is twofold: an injury labeled DILI may in fact be drug-induced AIH, particularly with interface activity and low-titer antibodies, and such patients warrant close follow-up rather than reassurance alone. In the post-ACS patient, where high-intensity statins are routine, a prior statin hepatitis should be flagged across care transitions, with early use of a PCSK9 inhibitor to avoid a dangerous rechallenge."
Autoimmune Hepatitis • Hepatitis C • Hepatology • Immunology • Inflammation
|
|
Hyun Hee Sul MD 1; Avneet Singh MD 1; Saba Altarawneh MD 2; Moniyka Sachar MD 1; Ammar Ismail MD 3; Krity Basnet MD 1; Shekwonya Damaris Sakoma MD 2; Amro B. Altarawneh MD 4; Dia'a Sarhan 5; Etan Spira MD 1
|